Document Detail

Drug-eluting stent thrombosis.
MedLine Citation:
PMID:  18432175     Owner:  NLM     Status:  MEDLINE    
When compared to bare metal stents (BMS), drug-eluting stents (DES) are associated with a dramatic reduction in restenosis and target lesion revascularization. However, the benefit of DES is limited to restenosis, and DES utilization does not translate into reductions in death or myocardial infarction. Additionally, concern exists regarding the long-term safety of DES, as there appears to be a small but real increase in late (LST) and very late stent thrombosis (VLST), seen particularly after the discontinuation of antiplatelet therapy. The specter of LST and VLST has curtailed enthusiasm for widespread DES utilization mandating critical appraisal of DES and the optimal role they play in percutaneous coronary intervention. The incidence of DES thrombosis is debated and varies somewhat by definition. The mechanisms are multifactorial, and involve patient, lesion, stent and physician related factors. Some of these factors are modifiable at the physician-patient level, while others are not. This review focuses on DES thrombosis, with particular attention paid to the definitions, incidence, mechanisms and clinical implications.
D H Steinberg; L F Satler
Related Documents :
21078975 - Exogenously administered secreted frizzled related protein 2 (sfrp2) reduces fibrosis a...
9669245 - Six-month angiographic and clinical follow-up of patients prospectively randomized to r...
11757505 - Decreased rate of coronary restenosis after lowering of plasma homocysteine levels.
12161225 - Technical feasibility, safety, and clinical outcome of stenting of unprotected left mai...
21793165 - Comparison of zotarolimus- versus everolimus-eluting stents in the treatment of coronar...
3306505 - Cardiac output in a fetus with erythroblastosis fetalis: assessment using pulsed doppler.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Minerva cardioangiologica     Volume:  56     ISSN:  0026-4725     ISO Abbreviation:  Minerva Cardioangiol     Publication Date:  2008 Feb 
Date Detail:
Created Date:  2008-04-24     Completed Date:  2008-06-26     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0400725     Medline TA:  Minerva Cardioangiol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  127-37     Citation Subset:  IM    
Division of Cardiology, Washington Hospital Center, Washington, DC 20010, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angioplasty, Transluminal, Percutaneous Coronary / methods
Coronary Artery Disease / therapy
Coronary Restenosis / prevention & control
Coronary Thrombosis / etiology*,  physiopathology,  prevention & control
Drug-Eluting Stents / adverse effects*
Risk Factors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Drug-eluting stents in patients with end-stage renal disease.
Next Document:  Antiplatelet therapy following drug-eluting stent implantation: new clinical data and recommendation...